Catalyst Pharmaceuticals Inc [CPRX] stock prices are up 1.20% to $14.35 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CPRX shares have gain 4.06% over the last week, with a monthly amount glided 0.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE. In a post published today on Yahoo Finance, Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE® (vamorolone) at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on December 21, 2023, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $30. Previously, ROTH Capital downgraded its rating to Neutral on August 24, 2022, and elevated its price target to $15.50. On September 21, 2018, Cantor Fitzgerald initiated with a Overweight rating. Piper Jaffray upgraded its rating to a Overweight. Piper Jaffray downgraded its rating to Neutral for this stock on April 26, 2016, and downed its price target to $1. In a note dated September 30, 2014, ROTH Capital reiterated an Buy rating on this stock and boosted its target price from $5 to $6.
The stock price of Catalyst Pharmaceuticals Inc [CPRX] has been fluctuating between $11.09 and $18.22 over the past year. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $14.35 at the most recent close of the market. An investor can expect a potential return of 35.05% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
The Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 348.39M for trailing twelve months, representing a surge of 79.39%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.21 points at the first support level, and at 14.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.45, and for the 2nd resistance point, it is at 14.54.
Catalyst Pharmaceuticals Inc [CPRX] reported earnings per share of -$0.29 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.28/share, meaning a difference of -$0.01 and a surprise factor of -3.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.33 per share as compared to estimates of $0.36 per share, a difference of -$0.03 representing a surprise of -8.30%.
Ratios To Look Out For
It’s worth pointing out that Catalyst Pharmaceuticals Inc [NASDAQ:CPRX]’s Current Ratio is 3.32. Further, the Quick Ratio stands at 3.17, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 4.43, the price to book ratio is 4.39 and price to earnings (TTM) ratio is 27.21.
Transactions by insiders
Recent insider trading involved Harper Molly, Director, that happened on Dec 15 when 14000.0 shares were sold. Director, Tierney David S completed a deal on Dec 12 to sell 50000.0 shares. Meanwhile, VP, Treasurer and CFO GRANDE ALICIA sold 60000.0 shares on Dec 11.
